Advertisement
U.S. markets closed

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.2500+0.1200 (+3.83%)
At close: 04:00PM EDT
3.2500 0.00 (0.00%)
After hours: 07:41PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close3.1300
Open3.6400
Bid2.5600 x 200
Ask3.2900 x 100
Day's Range3.2000 - 3.6400
52 Week Range2.9200 - 44.0000
Volume147,435
Avg. Volume32,291
Market Cap8.169M
Beta (5Y Monthly)0.31
PE Ratio (TTM)N/A
EPS (TTM)-10.2000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LGVN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Longeveron Inc.
    Analyst Report: PerkinElmer, Inc.PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes prenatal screening and infectious-disease testing, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening to environmental analytical tools.
    Rating
    Fair Value
    Economic Moat
    3 years agoMorningstar
View more
  • GlobeNewswire

    Longeveron Announces 1-for-10 Reverse Stock Split

    MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that the Company’s Board of Directors has approved a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (the “common stock”) (the “Reverse Split”). The Reverse Split was previously approved by

  • Simply Wall St.

    Longeveron Full Year 2023 Earnings: EPS Misses Expectations

    Longeveron ( NASDAQ:LGVN ) Full Year 2023 Results Key Financial Results Net loss: US$22.2m (loss widened by 18% from FY...

  • Insider Monkey

    Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript

    Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript February 27, 2024 Longeveron Inc. misses on earnings expectations. Reported EPS is $-0.25 EPS, expectations were $-0.21. FDS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, good afternoon, and […]